Isentio


Pathogenomix is a company dedicated to rapid and accurate pathogen identification using DNA/RNA sequencing technologies. Their solutions, including Ripseq software and databases, enable fast, reliable microbial detection in clinical and environmental samples without the need for extensive bioinformatics resources. They have received FDA Breakthrough Device Designation for their innovative diagnostic tools, aiming to improve infectious disease treatment and microbiological diagnostics.

Industries

biotechnology
information-services-f579
information-technology-dbca
medical
software

Nr. of Employees

small (1-50)


Products

Targeted sequencing analysis service for NGS data

Analysis workflow that preprocesses targeted NGS reads locally to minimize upload, then performs cloud-based taxonomic identification against curated databases and generates reports for clinical/research use.

Sanger sequencing mixed-sample analysis tool

Online application to interpret mixed Sanger chromatograms, perform bulk uploads, apply confidence flags aligned to clinical sequencing guidelines, and generate reports for single and mixed-organism samples.

Targeted NGS clinical assay under regulatory review

A targeted 16S-based NGS assay and accompanying protocols and databases developed for clinical pathogen identification; noted as having received an FDA Breakthrough Device designation and not marketed until regulatory clearance.


Services

Cloud-based sequencing analysis SaaS for pathogen identification

Browser-accessible software service that ingests Sanger and targeted NGS data, performs preprocessing and taxonomic identification against curated reference databases, and produces automated reports.

Curated microbial reference database subscription and curation tools

Curated marker-gene reference databases with automated filters, taxonomy cross-referencing, and user tools to annotate, approve, or reject references to build medically relevant reference sets.

Protocol and primer development resources

Laboratory protocols and primer designs for PCR amplification of marker genes used in targeted sequencing workflows (available as downloadable protocols).

Regulatory support through development of targeted NGS clinical assay

Development activities for a targeted NGS clinical assay that has been assigned FDA Breakthrough Device designation; regulatory guidance and data-generation support for submission pathways.

Expertise Areas

  • Clinical infectious-disease diagnostics
  • Targeted metagenomic (amplicon) sequencing
  • Polymicrobial sample analysis and mixed-chromatogram interpretation
  • Clinical bioinformatics and cloud-based analysis pipelines
  • Show More (4)

Key Technologies

  • Targeted amplicon next-generation sequencing (NGS)
  • Sanger sequencing analysis
  • Long-read sequencing (nanopore) support
  • Cloud-based SaaS analytics
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.